Skip to main content

Amgen Inc(AMGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low281.41
Day High285.57
Open:281.95
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest News

AMGEN ANNOUNCES WEBCAST OF 2022 EVERCORE ISI HEALTHCARE CONFERENCE
PR Newswire - Wed Nov 23, 3:00PM CST
PR Newswire
Wed Nov 23, 3:00PM CST
/PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 11:20 a.m. ET on Tuesday, November 29, 2022. David M. Reese,...
2 Stocks to Buy Whether or Not a Recession Is Coming
Motley Fool - Fri Nov 18, 8:37AM CST
Motley Fool
Fri Nov 18, 8:37AM CST
Both have outperformed the stock market this year.
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
BayStreet.ca - Tue Nov 15, 8:30AM CST
BayStreet.ca
Tue Nov 15, 8:30AM CST
USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billion, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is still reaping the drug’s benefit...

Latest Articles